At the same time, the FDA sent warning letters to dozens of specific companies for making false or misleading claims about their compounded GLP-1 drugs
And in short that came out a few years after that STEP 1 trial what we did for the very first time is take individuals with obesity and pre-existing cardiovascular disease, like a prior stroke, prior heart attack, or peripheral arterial disease, called PAD, and they're on maximal therapy for their cardiovascular disease or stroke, and then randomized them on top of that to either semaglutide or placebo
Can be split across morning and evening
How do I add creatine to my diet
Oral GLP-1s (Lillys paltusotine-orforglipron, etc.) are expected in late 2025/2026, and might be covered differently (some plans treat orals less restrictively than injectables)
The Honest Answer At normal therapeutic doses, supervised by a qualified doctor, with branded pharmaceutical-grade vials, the safety profile is reasonable